Abstract:Background: In the LIBERTY Long-Term Extension study, once-daily relugolix combination therapy (40 mg relugolix, estradiol 1 mg, norethindrone acetate 0.5 mg) substantially improved uterine fibroid-associated heavy menstrual bleeding throughout the 52-week treatment period in the overall study population. Objective: Black or African American women typically experience a greater extent of disease and symptom burden of uterine fibroids vs other racial groups and have traditionally been underrepresented in clinical trials. This secondary analysis aimed to assess the efficacy and safety of relugolix combination therapy in the subgroup population of Black or African American women with uterine fibroids in the LIBERTY Long-Term Extension study. Study design: Black or African American premenopausal women (aged 18-50 years) with uterine fibroids and heavy menstrual bleeding who completed the 24-week randomized, placebo-controlled, double-blind LIBERTY 1 (identifier: NCT03049735) or LIBERTY 2 (identifier: NCT03103087) trials were eligible to enroll in the 28-week LIBERTY Long-Term Extension study (identifier: NCT03412890), in which all women received once-daily, open-label relugolix combination therapy. The primary endpoint of this subanalysis was the proportion of Black or African American treatment responders: women who achieved a menstrual blood loss volume of <80 mL and at least a 50% reduction in menstrual blood loss volume from the pivotal study baseline to the last 35 days of treatment by pivotal study randomized treatment group. The secondary outcomes included rates of amenorrhea and changes in symptom burden and quality of life. Results: Overall, 241 of 477 women (50.5%) enrolled in the LIBERTY Long-Term Extension study self-identified as Black or African American. In Black or African American women receiving continuous relugolix combination therapy for up to 52 weeks, 58 of 70 women (82.9%; 95% confidence interval, 72.0%-90.8%) met the treatment responder criteria for reduction in heavy menstrual bleeding (primary endpoint). A substantial reduction in menstrual blood loss volume from the pivotal study baseline to week 52 was demonstrated (least squares mean percentage change: 85.0%); 64.3% of women achieved amenorrhea; 59.1% of women with anemia at the pivotal study baseline achieved a substantial improvement (>2 g/dL) in hemoglobin levels; and decreased symptom severity and distress because of uterine fibroid-associated symptoms and improvements in health-related quality of life through 52 weeks were demonstrated. The most frequently reported adverse events during the cumulative 52-week treatment period were hot flush (12.9%), headache (5.7%), and hypertension (5.7%). Bone mineral density was preserved through 52 weeks. Conclusion: Once-daily relugolix combination therapy improved uterine fibroid-associated heavy menstrual bleeding in most Black or African American women who participated in the LIBERTY Long-Term Extension study. The safety and efficacy profile of relugolix combination therapy in Black or African American women was consistent with previously published results from the overall study population through 52 weeks. Findings from this subanalysis will assist shared decision-making by helping providers and Black or African American women understand the efficacy and safety of relugolix combination therapy as a pharmacologic option for the management of uterine fibroid-associated symptoms.

An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids

Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis

Relugolix, Estradiol, Norethindrone Acetate (40mg+1.0mg+0.5mg), Oral Combination Therapy for Uterine Fibroids (Relugolix) in Premenstrual Women: A Quality Life Perspective

Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials

Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids

Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long‐term extension study: A descriptive subgroup analysis in women with anemia at baseline

Efficacy and Safety of Elagolix 150 mg QD in Women With Uterine Fibroids and Heavy Menstrual Bleeding [A87]

Impact of demographic and clinical factors on elagolix plus add-back therapy effects on patient-reported nonbleeding symptoms in women with heavy menstrual bleeding and uterine fibroids: a post hoc analysis of data from two clinical trials

The potential role of elagolix for treating uterine bleeding associated to uterine myomas

GnRH analogs for the treatment of heavy menstrual bleeding associated with uterine fibroids

Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary

Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain

Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study

The modern management of uterine fibroids-related abnormal uterine bleeding

Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids

Elagolix with Add-Back Therapy in Women with Heavy Menstrual Bleeding, Uterine Fibroids, and Anemia: Subgroup Analysis of Two Phase 3 Trials

Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis

Presurgical treatment of uterine myomas with the GnRH-antagonist relugolix in combination therapy: an observational study